Evidence supporting the use of: Omega-3
For the health condition: Macular Degeneration

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega-3 fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), have been studied for their potential role in supporting eye health and preventing or slowing the progression of age-related macular degeneration (AMD). The rationale behind their use is based on the high concentration of DHA in the retina and its importance in maintaining retinal structure and function. Early observational studies suggested that higher dietary intake of omega-3 fatty acids was associated with a reduced risk of developing AMD. However, more recent and rigorous clinical trials have provided mixed results.

The largest randomized controlled trial to date, the Age-Related Eye Disease Study 2 (AREDS2), found that supplementation with omega-3 fatty acids did not significantly reduce the risk of progression to advanced AMD compared to placebo. Other meta-analyses and systematic reviews have reached similar conclusions, suggesting little to no benefit from omega-3 supplementation for AMD prevention or treatment, though some data indicate possible benefit for early-stage AMD or in populations with low dietary omega-3 intake.

In summary, while there is a scientific rationale and some early supportive evidence, high-quality clinical trial data do not robustly support the use of omega-3 supplements for macular degeneration. The evidence rating is therefore moderate to low.

More about Omega-3
More about Macular Degeneration

Products containing Omega-3

We currently have no products on Vitabase that contain this ingredient.